MET and glioma: Dual receptor targeting of EGFR and c-Met, possible using certain bivalent antibody approaches [28–30], may be reasonable combination therapeutic targets in high grade glial tumors based on expression studies [31–35] from which one DIPG clinical trial employing the EGFR inhibitor, erlotinib, has opened [NCT01182350].